Clinical Trials on Polymorphism, Genetic in Australia

Total 965 results

Orphatech Pharmaceuticals, GmbH

Withdrawn

Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A

Molybdenum Cofactor Deficiency Type A

Australia
Ikaria Bioscience Pty Ltd

Not yet recruiting

Study of RN0361 in Adult Subjects

Hypertriglyceridemia | Familial Chylomicronemia

Australia
Medical University of Graz

Completed

Evaluation of an App for Smartphones for People With a Bipolar Affective Disorder

Bipolar Affective Disorder

Austria
Bond Biosciences

Terminated

A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

Hereditary Hemochromatosis

Australia
Holostem Terapie Avanzate s.r.l.
Paracelsus Medical University

Terminated

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17) (HOLOGENE17)

Junctional Epidermolysis Bullosa

Austria
Murdoch Childrens Research Institute

Completed

Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD

Facio-Scapulo-Humeral Dystrophy | FSHD2 | FSHD1

Australia
Flatley Discovery Lab LLC

Completed

A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants

Cystic Fibrosis

Australia
CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
ModernaTX, Inc.

Recruiting

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria

Phenylketonuria

United States, Australia
Baxalta now part of Shire
Baxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)

Completed

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Alpha 1-Antitrypsin Deficiency

Australia, New Zealand
LEO Pharma

Completed

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

Atopic Dermatitis

Austria
Pfizer
Pfizer

Completed

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

Sickle Cell Disease

Australia, United States
Medical University of Vienna

Completed

Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis

Atopic Dermatitis

Austria
The Alfred

Unknown

A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (CISTIC)

Cystic Fibrosis

Australia
Medical University of Vienna

Completed

FACE-Q in Blepharoplasty

Dermatochalasis of Upper Eyelid

Austria
Stefan Woehrl
Medical University of Vienna

Completed

Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments

Atopic Dermatitis

Austria
Foundation for Angelman Syndrome Therapeutics,...
Queensland University of Technology

Recruiting

The Global Angelman Syndrome Registry (GASR)

Angelman Syndrome

Australia
Regeneron Pharmaceuticals
Sanofi

Completed

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Germany, New Zealand, Australia
The University of Queensland
Telethon Kids Institute

Completed

Prevention of Bronchiectasis in Infants With Cystic Fibrosis (COMBATCF)

Bronchiectasis | Cystic Fibrosis

Australia, New Zealand
Spark Therapeutics
Children's Hospital of Philadelphia; University of Pittsburgh; St. James's Hospital... and other collaborators

Terminated

Hemophilia B Gene Therapy With AAV8 Vector

Hemophilia B

United States, Australia
Bayside Health

Unknown

Modified Release Posaconazole in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
The Alfred

Unknown

CPET in CF Patients With One G551D Mutation Taking VX770

Cystic Fibrosis

Australia
Gilead Sciences

Completed

Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis

Australia
Premier Specialists, Australia

Unknown

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Epidermolysis Bullosa Simplex | Epidermolysis Bullosa Simplex Kobner | Weber-Cockayne Syndrome

Australia
Amicus Therapeutics

Completed

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

Fabry Disease

Australia
Barwon Health
National Health and Medical Research Council, Australia; University of Melbourne

Completed

Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

Graves' Ophthalmopathy

Australia
Gilead Sciences

Withdrawn

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis | Mucociliary Clearance

Australia
4D Molecular Therapeutics

Active, not recruiting

4D-310 in Adults With Fabry Disease and Cardiac Involvement

Fabry Disease

Taiwan, Australia
Amicus Therapeutics

Completed

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Fabry Disease

Australia, Brazil
Medical University of Vienna

Completed

Effects of Creatine Supplementation in Rett Syndrome

Rett Syndrome

Austria
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Completed

Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation

Cystic Fibrosis

Australia
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Unknown

Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Cystic Fibrosis

Australia
Glycomine, Inc.

Recruiting

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Pmm2-CDG

Spain, Australia, United States
Western Sydney Local Health District

Recruiting

Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT)

Ventricular Tachycardia | Cardiomyopathy, Dilated | Heart Disease Structural Disorder | Sarcoidosis | Cardiomyopathy, Hypertrophic | Cardiomyopathy, Familial | Cardiomyopathy Ischemic | Arrhythmogenic Right Ventricular Cardiomyopathy 1 | Arrhythmogenic Left Ventricular Cardiomyopathy

Australia
AceLink Therapeutics, Inc.
Novotech (Australia) Pty Limited

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers

Autosomal Dominant Polycystic Kidney

Australia
Hospital Rudolfstiftung
Oesterreichische Muskelforschung

Completed

Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study

Carrier of Duchenne Muscular Dystrophy

Austria
Murdoch Childrens Research Institute
Melbourne Health; Austin Health; Royal Brisbane and Women's Hospital; The University... and other collaborators

Completed

Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary? (Mi-iron)

Hereditary Haemochromatosis

Australia
CSL Behring

Completed

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Hemophilia B

Germany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
Ultragenyx Pharmaceutical Inc
Abeona Therapeutics, Inc

Enrolling by invitation

A Long-term Follow-up Study of Patients With MPS IIIA Treated With ABO-102

Mucopolysaccharidosis III-A

United States, Australia, Spain
CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
Krystal Biotech, Inc.
Novotech (Australia) Pty Limited

Withdrawn

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Cystic Fibrosis

Australia
Holostem Terapie Avanzate s.r.l.
Paracelsus Medical University

Terminated

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB. (HOLOGENE7)

Recessive Dystrophic Epidermolysis Bullosa

Austria
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
University College, London
University of Sydney; University Hospital Birmingham

Unknown

Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases (FABRY400)

Fabry Disease

United Kingdom, Australia
Astellas Pharma Inc

Completed

Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis

Atopic Dermatitis

Australia, Belgium, Poland, Hungary, Portugal, Germany, Iceland, Malta
Melbourne Health
Sanofi

Withdrawn

Complement Activation in the Lysosomal Storage Disorders (CATALYST)

Lysosomal Storage Diseases | Fabry Disease | Niemann-Pick Disease, Type C | Gaucher Disease

Australia
National Eye Institute (NEI)

Recruiting

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Cone-Rod Degeneration | Rod-Cone Degeneration

United States, Australia
Bayside Health
Monash University; The Alfred

Unknown

The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation

Cystic Fibrosis

Australia

Clinical Trials on Polymorphism, Genetic in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations